Table 2 Treatment responder patients at month 3 and 6
DME responder patients | Month 3 (n/N) | Month 6 (n/N) | Additional responder patients (month 6 vs month 3) |
|---|---|---|---|
Aflibercept (Eylea®) | 93.48/190 | 130/190 | 36.52 |
Ranibizumab (Lucentis®) | 82.34/176 | 103/176 | 20.66 |
Bevacizumab (Avastin®) | 48.81/180 | 62/180 | 13.19 |